Quest Diagnostics Completes Acquisition of Clinical Outreach Operations of Dignity Health
News Jul 05, 2013
Quest Diagnostics announced that it has completed the previously announced acquisition of lab-related clinical outreach service operations of Dignity Health, a hospital system based in California.
Quest Diagnostics will perform testing for the acquired operations through its clinical laboratories in West Hills and Sacramento, Calif., and Las Vegas, Nevada. The acquisition includes patient service centers and associated business in parts of California and Nevada. Dignity Health's hospital-based laboratories are not included in the sale. Additional terms were not disclosed.
Quest Diagnostics continues to expect the transaction to be neutral to adjusted earnings in 2013 and modestly accretive to earnings per share in 2014. The company also expects it to contribute about half a percentage point to consolidated revenues annually.
The acquisition, which is the company's third of a laboratory business in 2013, is consistent with the five-point strategy described by Quest Diagnostics late last year. This strategy includes delivering disciplined capital deployment and driving one to two percent in growth per year through strategically aligned fold-in acquisitions. In May, the company announced it had acquired the toxicology and clinical laboratory business of medical center operator Concentra, a subsidiary of Humana Inc. In January, the company completed the acquisition of the clinical and anatomic-pathology outreach laboratory businesses of Massachusetts-based UMass Memorial Medical Center.
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018